Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F. Ladoire S, et al. Among authors: rederstorff e. Eur J Cancer. 2022 Apr;165:13-24. doi: 10.1016/j.ejca.2022.01.005. Epub 2022 Feb 1. Eur J Cancer. 2022. PMID: 35189537 Free PMC article.
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F. Fumet JD, et al. Among authors: rederstorff e. ESMO Open. 2018 Jun 19;3(4):e000375. doi: 10.1136/esmoopen-2018-000375. eCollection 2018. ESMO Open. 2018. PMID: 29942666 Free PMC article.
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F. Fumet JD, et al. Among authors: rederstorff e. BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x. BMC Cancer. 2020. PMID: 32778095 Free PMC article.
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M, Macaire P, Bellio H, Uwer L, Ilie S, Lorgis V, Hennequin A, Ladoire S, Rederstorff E, Fumoleau P, Isambert N, Bonnin N, You B, Freyer G, Desmoulins I, Schmitt A. Reda M, et al. Among authors: rederstorff e. Cancer Chemother Pharmacol. 2022 Feb;89(2):197-208. doi: 10.1007/s00280-021-04395-y. Epub 2022 Jan 8. Cancer Chemother Pharmacol. 2022. PMID: 34997290
Corrigendum to "Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer": [ESMO Open 3 (2018) e000375].
Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F. Fumet JD, et al. Among authors: rederstorff e. ESMO Open. 2023 Apr;8(2):101185. doi: 10.1016/j.esmoop.2023.101185. Epub 2023 Mar 1. ESMO Open. 2023. PMID: 36868156 Free PMC article. No abstract available.
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB. Piquemal D, et al. Among authors: rederstorff e. J Gastrointest Oncol. 2023 Apr 29;14(2):997-1007. doi: 10.21037/jgo-22-946. Epub 2023 Apr 10. J Gastrointest Oncol. 2023. PMID: 37201091 Free PMC article.
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. Roussot N, et al. Among authors: rederstorff e. BMC Cancer. 2023 Nov 9;23(1):1080. doi: 10.1186/s12885-023-11534-6. BMC Cancer. 2023. PMID: 37946136 Free PMC article. Clinical Trial.
Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction.
Mathieu E, Lamirault G, Toquet C, Lhommet P, Rederstorff E, Sourice S, Biteau K, Hulin P, Forest V, Weiss P, Guicheux J, Lemarchand P. Mathieu E, et al. Among authors: rederstorff e. PLoS One. 2012;7(12):e51991. doi: 10.1371/journal.pone.0051991. Epub 2012 Dec 20. PLoS One. 2012. PMID: 23284842 Free PMC article.
Pharmacological modulation of human mesenchymal stem cell chondrogenesis by a chemically oversulfated polysaccharide of marine origin: potential application to cartilage regenerative medicine.
Merceron C, Portron S, Vignes-Colombeix C, Rederstorff E, Masson M, Lesoeur J, Sourice S, Sinquin C, Colliec-Jouault S, Weiss P, Vinatier C, Guicheux J. Merceron C, et al. Among authors: rederstorff e. Stem Cells. 2012 Mar;30(3):471-80. doi: 10.1002/stem.1686. Stem Cells. 2012. PMID: 22131189 Free PMC article.
12 results